Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

NF-κB is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis

Abstract

Oncogenic mutations in ras lead to constitutive activation of downstream signaling pathways that modulate the activities of transcription factors. In turn, these factors control the expression of a subset of genes responsible for neoplastic cell transformation. Recent studies suggest that transcription factor NF-κB contributes to cell transformation by inhibiting the cell death signal activated by oncogenic Ras. In this study, inhibition of NF-κB activity by forced expression of a super-repressor form of IκBα, the major inhibitor of NF-κB, markedly decreased the growth rate, saturation density and tumorigenicity of oncogenic H-Ras transformed rat embryo fibroblasts. Such clonally isolated cells overexpressing IκBα super-repressor not only were viable but also exhibited no sign of spontaneous apoptosis. Inhibition of NF-κB in these cells was functionally demonstrated by both the loss of cytokine induced DNA binding activity and a profoundly increased sensitivity to cell death in response to TNF-α treatment. In contrast, inhibition of NF-κB activity in non-transformed fibroblasts had minimal effect on growth, but rendered the cells resistant to a subsequent transformation by H-ras oncogene. Similar results were also obtained with rat intestinal epithelial cells harboring an inducible ras oncogene. Taken together, these findings suggest that NF-κB activity is essential for abnormal cell proliferation and tumorigenicity activated by the ras oncogene and highlight an alternative functional role for NF-κB in oncogenic Ras-mediated cell transformation that is distinct from its anti-apoptotic activity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Ahmad M, Marui N, Alexander RW and Medford RM. . 1995 J. Biol. Chem. 270: 8976–8983.

  • Antwerp DJV, Seamus JM, Kafri T, Green DR and Verma IM. . 1996 Science 274: 787–789.

  • Baeuerle PA and Baltimore D. . 1996 Cell 87: 13–20.

  • Baldwin Jr AS. . 1996 Ann. Rev. Immunol. 14: 649–681.

  • Barbacid M. . 1987 Ann. Rev. Biochem. 56: 779–827.

  • Bargou RC, Emmerich F, Krappman D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C and Dörken B. . 1997 J. Clin. Inv. 100: 2961–2969.

  • Beg A and Baltimore D. . 1996 Science 274: 782–784.

  • Brockman JA, Scherer DC, McKinsey TA, Hall SM, Qi X, Lee WY and Ballard DW. . 1995 Mol. Cell. Biol. 15: 2809–2818.

  • Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC. . 1998 Science 282: 1318–1321.

  • Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH and Ballard DW. . 1997 Proc. Natl. Acad. Sci. USA 94: 10057–10062.

  • Downward J. . 1997 Curr. Biol. 7: R258–260.

  • Downward J. . 1998 Curr. Opin. Genet. Dev. 8: 49–54.

  • Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ and Baldwin AS. . 1997 J. Biol. Chem. 272: 24113–24116.

  • Guttridge DC, Albanese C, Reuther JY, Pestell RG and Baldwin Jr AS. . 1999 Mol. Cell. Biol. 19: 5785–5799.

  • Higgins AK, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA and Narayanan R. . 1993 Proc. Natl. Acad. Sci. USA 90: 9901–9905.

  • Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C and Strauss M. . 1999 Mol. Cell. Biol. 19: 2690–2698.

  • Johnson R, Spiegelman B, Hanahan D and Wisdom R. . 1996 Mol. Cell. Biol. 16: 4504–4511.

  • Joyce D, Bouzahzah B, Fu M, Albanese C, D'Amico M, Steer J, Klein JU, Lee RJ, Segall JE, Westwick JK, Der CJ and Pestell RG. . 1999 J. Biol. Chem. 274: 25245–25249.

  • Kaltschmidt B, Kaltschmidt C, Hehner SP, Droge W and Schmitz ML. . 1999 Oncogene 18: 3213–3225.

  • Kauffman-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J and Evan G. . 1997 Nature 385: 544–548.

  • Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH and Downward J. . 1997 EMBO J. 16: 2783–2793.

  • Kiaris H and Spandidos DA. . 1995 Intl. J. Oncol. 7: 413.

  • Ko TC, Sheng HM, Reisman D, Thompson EA and Beauchamp RD. . 1995 Oncogene 10: 177–184.

  • Koumenis C and Giaccia A. . 1997 Mol. Cell. Biol. 17: 7306–7316.

  • Langer SJ, Bortner DM, Roussel MF, Sherr CJ and Ostrowski MC. . 1992 Mol. Cell. Biol. 12: 5355–5362.

  • Ledebur HC and Parks TP. . 1995 J. Biol. Chem. 270: 933–943.

  • Lewis H, Kaszubska W, DeLamarter JF and Whelan J. . 1994 Mol. Cell. Biol. 14: 5701–5709.

  • Liang P, Averboukh L, Zhu W and Pardee AB. . 1994 Proc. Natl. Acad. Sci. USA 91: 12515–12519.

  • Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M and Lowe SW. . 1998 Genes Dev. 12: 3008–3019.

  • Liu JJ, Chao JR, Jiang MC, Ng SY, Yen JJ and Yang-Yen HF. . 1995 Mol. Cell. Biol. 15: 3654–3663.

  • Liu Z, Hsu H, Goeddel DV and Karin M. . 1996 Cell 87: 565–576.

  • Lowy DR and Willumsen BM. . 1993 Ann. Rev. Biochem. 62: 851–891.

  • Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ and Baldwin AS. . 1997 Science 278: 1812–1815.

  • Narayanan R, Higgins KA, Perez JR, Coleman TA and Rosen CA. . 1993 Mol. Cell. Biol. 13: 3802–3810.

  • Romashkova JA and Makarov SS. . 1999 Nature 401: 86–90.

  • Schreiber E, Matthias P, Muller M and Schaffner W. . 1989 Nucleic Acids Res. 17: 6419.

  • Sen R and Baltimore D. . 1986 Cell 46: 705–716.

  • Takeuchi M and Baichwal VR. . 1995 Proc. Natl. Acad. Sci. USA 92: 3561–3565.

  • Treisman R. . 1994 Curr. Opin. Genet. Dev. 4: 96–101.

  • Verma IM, Stevenson JK, Schwarz EM, Antwerp DV and Miyamoto S. . 1995 Genes Dev. 9: 2723–2735.

  • Vojtek AB and Der CJ. . 1998 J. Biol. Chem. 273: 19925–19928.

  • Wang C, Mayo MW and Baldwin AS. . 1996 Science 274: 784–787.

  • White MA, Nicolette C, Minden A, Polverino A, Aelst LV, Karin M and Wigler MH. . 1995 Cell 80: 533–541.

  • Yamit-Hezi A and Dikstein R. . 1998 EMBO J. 17: 5161–5169.

  • You M, Ku PT, Hrdlickova R and Bose Jr HR. . 1997 Mol. Cell. Biol. 17: 7328–7341.

  • Zhu J, Woods D, McMahon M and Bishop JM. . 1998 Genes Dev. 12: 2997–3007.

Download references

Acknowledgements

We thank R Wisdom, C Aiken, X Wang for kindly providing the retroviral vectors and plasmids; L Marnett and T Daniel for critical reading of the manuscript. This work was supported in part by grants, CA76960 and CA74067 from the National Institute of Health (P Liang), AI33839 from the National Institute of Allergy and Infectious Diseases (DW Ballard) and funds from the Vanderbilt Cancer Center (P Liang) and the Howard Hughes Medical Institute (DW Ballard).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jo, H., Zhang, R., Zhang, H. et al. NF-κB is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene 19, 841–849 (2000). https://doi.org/10.1038/sj.onc.1203392

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203392

Keywords

This article is cited by

Search

Quick links